Afatinib
| CAS No. | 850140-72-6 |
|---|---|
| MDL No. | MFCD31630115 |
| MF | C24H25ClFN5O3 |
| MW | 485.90 |
| InChI Key | ULXXDDBFHOBEHA-CWDCEQMOSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Afatinib is a quinazoline compound with a 3-chloro-4-fluoroanilino group at the 4-position, a 4-dimethylamino-trans-but-2-enamido group at the 6-position, and an (S)-tetrahydrofuran-3-yloxy group at the 7-position. It is used as its dimaleate salt for first-line treatment of metastatic non-small cell lung cancer. It functions as a tyrosine kinase inhibitor and antineoplastic agent. It belongs to quinazolines, furans, organofluorine compounds, enamides, aromatic ethers, tertiary amines, monochlorobenzenes, and secondary carboxamides.
| CAS No. | 850140-72-6 |
|---|---|
| Product Name | Afatinib |
Biological Targets
EGFR·ERBB2·ERBB4
Associated Conditions
breast neoplasm·lung neoplasm·brain cancer·prostate adenocarcinoma·colorectal neoplasm·
* The information provided here is compiled from public sources and is for reference only.
